Thomas M Lane

US Patent:

20040096446, May 20, 2004

Filed:

Nov 12, 2003

Appl. No.:

10/344833

Inventors:

Thomas Lane - Irvine CA, US

International Classification:

A61K039/395

US Classification:

424/145100

Abstract:

The invention provides a method of reducing the severity and reversing the neurological effects of a demyelinating disease in a subject by administering to a subject having a demyelinating disease an effective amount of a neutralizing agent specific for interferon inducible protein of 10 kDa (IP-10). The methods of the invention promote remyelination of demyelinated nerve fibers and impede further demyyelination of nerve fibers in a subject affected with a demyelinating disease by administering to a subject having a demyelinating disease.

US Patent:

20050025744, Feb 3, 2005

Filed:

Jul 29, 2004

Appl. No.:

10/903118

Inventors:

Thomas Lane - Irvine CA, US

International Classification:

A61K039/395
A61K038/21

US Classification:

424085600, 424145100, 514002000

Abstract:

The invention discloses methods and compositions for treating Multiple Sclerosis through the administration of humanized anti-IP-10 antibody in combination with an additional therapeutic compound.

US Patent:

20050053600, Mar 10, 2005

Filed:

Sep 9, 2004

Appl. No.:

10/938673

Inventors:

Thomas Lane - Irvine CA, US

International Classification:

A61K039/395

US Classification:

424141100, 424146100

Abstract:

The invention discloses methods and compositions for treating rheumatoid arthritis through the administration of humanized anti-IP-10 antibody alone or in combination with an additional anti-rheumatic therapeutic compound.

US Patent:

20080019973, Jan 24, 2008

Filed:

Jul 29, 2003

Appl. No.:

10/549482

Inventors:

Thomas E. Lane - Irvine CA, US
Daniela J.J. Carr - Edmond OK, US

International Classification:

A61K 39/395
A01K 67/00
C07K 16/24
C12Q 1/18
C12Q 1/68
G01N 33/53

US Classification:

4241451, 435 32, 435 6, 435 792, 800 9

Abstract:

The invention provides a method of reducing ocular inflammation in an individual susceptible to ocular inflammation. The method involves administering to the individual an effective amount of a neutralizing agent specific for CXCL10. Also provided is a method for reducing spread of viral infection within ocular tissues of an individual susceptible to ocular viral infection, which involves administering to the individual an effective amount of a neutralizing agent specific for CXCL10. Further provided is a method of extending corneal graft survival following corneal transplantation in an individual, which involves administering to said individual an effective amount of a neutralizing agent specific for CXCL10. Additionally, the invention provides a method for identifying a compound for reducing ocular inflammation in an animal.